Skip to content


  • Oral presentation
  • Open Access

Pretreatment with levosimendan improves outcome in off-pump coronary artery bypass grafting

Journal of Cardiothoracic Surgery20138 (Suppl 1) :O159

  • Published:


  • Placebo
  • Cardiac Output
  • Pulmonary Artery
  • Systolic Function
  • Baseline Measurement


Levosimendan, calcium sensitizer, induces contractility by binding to troponin C without increasing intracellular calcium concentration. We tested the hypothesis that levosimendan could produce early and prolonged beneficial effect on left ventricular (LV) systolic function in patients with normal LV function undergoing off-pump coronary artery bypass grafting (OPCABG).


Loading dose of levosimendan at low-dose (12 mcg/kg), high-dose (24 mcg/kg) or placebo were administered in thirty-one patients in randomized controlled study. Bolus thermodilution by pulmonary artery catheter used for cardiac output (CO) measuring. Numerical data were described by median. To compare the three independent groups (low or high-dose levosimendan or placebo) the Kruskal-Walis test was applied. For comparing time points in one group, we tested the differences in time within each group with the Friedman test.


Significant increase in CO occurred after low-dose (p = 0.001) and high-dose levosimendan (p < 0.001). CO was higher in all measurements in patients receiving low-dose levosimendan versus patients received placebo, but didn't rich significance. In patients receiving low-dose levosimendan, compared with baseline measurement, CO was higher 20 minutes after infusion (p = 0.080) and 48 h after surgery (p=0.067). Similar alteration in CO measurements occurred after high-dose comparing with low-dose levosimendan. Furthermore, CO was significantly higher in patients receiving high-dose levosimendan compared with those receiving placebo, 20 min after infusion (p = 0.021) and 48 h after surgery (p = 0.006). Compared with baseline measurement, all values of CO were significantly higher in patients treated with high-dose levosimendan (p = 0.005 for all).


Levosimendan produces early and prolonged beneficial effect on left ventricular performance in patients with preoperative normal LV function undergoing OPCABG surgery, and this effect is dose dependent.

Authors’ Affiliations

Clinic of Anesthesiology, Reanimatology and Intensive Medicine, University Hospital Dubrava, Zagreb, Croatia


© Husedzinovic and Bradic; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.